Allosteric Crosstalk between Inhibitor Binding Sites Drives Enhanced Islatravir Susceptibility in F227C HIV-1 Reverse Transcriptase
ACS Infectious Diseases · 11.09.2026 · 12 (9) · 3179-3190
DOI: 10.1021/acsinfecdis.6c00431 ↗Kurz gefasst
Fachartikel in der Zeitschrift ACS Infectious Diseases, online erschienen am 07.08.2026. Verfasst von Corey W Hecksel und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Protein & Structural Chemistry, Merck & Co., Inc., West Point, Pennsylvania19486, United States. Hauptthemen laut MEDLINE: HIV Reverse Transcriptase, HIV-1, Triazoles, Reverse Transcriptase Inhibitors. Die Arbeit nennt 66 Literaturangaben.
Abstract (Originalsprache)
Doravirine (DOR) and islatravir (ISL) are inhibitors of human immunodeficiency virus type 1 (HIV-1) replication that block the viral reverse transcriptase (RT) by distinct mechanisms. The combination has demonstrated efficacy in Phase 3 clinical studies in both virologically suppressed and treatment-naïve people living with HIV-1 and has the potential to mitigate the emergence of resistance-associated mutations through complementary virological profiles. RT bearing a single point mutation, F227C, is associated with resistance to DOR, yet is hypersusceptible to ISL. Here, we report cryoEM structures of islatravir triphosphate (ISL-TP) bound to wild-type (WT) RT and F227C RT. Comparison with the corresponding ISL-TP and dATP-bound WT RT structures reveals that the F227C mutation induces an unexpected conformational change in a loop of the palm domain that is positioned to gate substrate access, providing a structural basis for ISL hypersusceptibility.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Protein & Structural Chemistry, Merck & Co., Inc., West Point, Pennsylvania19486, United States.
- Department of Discovery Chemistry, Merck & Co., Inc., West Point, Pennsylvania19486, United States.
- Department of Infectious Diseases, Merck & Co., Inc., West Point, Pennsylvania19486, United States.
- Department of Structural Biology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania15213, United States.
ORCID-Profile: Corey W Hecksel, Susanne N Walker, Izzat Raheem, Guillermo Calero, Sandra B Gabelli, Daniel J Klein
Zitieren
APA
Hecksel, C. W., Walker, S. N., Raheem, I., Asante-Appiah, E., Calero, G., Diamond, T. L., Gabelli, S. B., Gomez-Llorente, Y., Hayes, R. P., Tummala, S., Vergara, S., & Klein, D. J. (2026). Allosteric Crosstalk between Inhibitor Binding Sites Drives Enhanced Islatravir Susceptibility in F227C HIV-1 Reverse Transcriptase. ACS Infectious Diseases, 12(9), 3179-3190. https://doi.org/10.1021/acsinfecdis.6c00431
Vancouver
Hecksel CW, Walker SN, Raheem I, Asante-Appiah E, Calero G, Diamond TL, et al. Allosteric Crosstalk between Inhibitor Binding Sites Drives Enhanced Islatravir Susceptibility in F227C HIV-1 Reverse Transcriptase. ACS Infectious Diseases. 2026;12(9):3179-3190. doi:10.1021/acsinfecdis.6c00431
BibTeX
@article{Hecksel2026,
author = {Hecksel, Corey W and Walker, Susanne N and Raheem, Izzat and Asante-Appiah, Ernest and Calero, Guillermo and Diamond, Tracy L and Gabelli, Sandra B and Gomez-Llorente, Yacob and Hayes, Robert P and Tummala, Srivanya and Vergara, Sandra and Klein, Daniel J},
title = {Allosteric Crosstalk between Inhibitor Binding Sites Drives Enhanced Islatravir Susceptibility in F227C HIV-1 Reverse Transcriptase},
journal = {ACS Infectious Diseases},
year = {2026},
volume = {12},
number = {9},
pages = {3179--3190},
doi = {10.1021/acsinfecdis.6c00431}
}
EUVIMED